Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

602
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
602
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

5.0K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
5.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

3.0K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Immunological Evaluation of Pel-Derived Glycoconjugate Vaccine Candidates against <i>Pseudomonas aeruginosa</i>.

JACS Au·2026
Same author

Immune responses to glycoconjugate vaccines rely on a balance between polysaccharide length and glycosylation density.

Carbohydrate polymers·2026
Same author

Vaccines preventing neonatal sepsis: focus on Group B <i>Streptococcus</i>, <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> to combat rising antimicrobial resistance.

Expert review of vaccines·2026
Same author

An mRNA-based FimH nanoparticle vaccine against uropathogenic <i>Escherichia coli</i> is highly immunogenic in rodents.

Frontiers in immunology·2025
Same author

Synthesis, Conformal Analysis, and Antibody Binding of Staphylococcus aureus Capsular Polysaccharide Type 5 Oligosaccharides.

Angewandte Chemie (International ed. in English)·2025
Same author

Multimeric, multivalent fusion carrier proteins for site-selective glycoconjugate vaccines simultaneously targeting <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>.

Chemical science·2025
Same journal

Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.

Human vaccines & immunotherapeutics·2026
Same journal

The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.

Human vaccines & immunotherapeutics·2026
Same journal

Correction.

Human vaccines & immunotherapeutics·2026
Same journal

Vaccination practice and safety in children with special health care needs: A retrospective study of 1278 children.

Human vaccines & immunotherapeutics·2026
Same journal

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human vaccines & immunotherapeutics·2026
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

9.3K

Vaccines against Clostridium difficile.

Rosanna Leuzzi1, Roberto Adamo1, Maria Scarselli1

  • 1Novartis Vaccines S.r.L.; Siena, Italy.

Human Vaccines & Immunotherapeutics
|March 19, 2014
PubMed
Summary
This summary is machine-generated.

Developing vaccines against Clostridium difficile infection (CDI) offers a promising strategy to combat this severe nosocomial disease. Current research focuses on novel antigens and clinical trials to overcome treatment challenges and recurring infections.

Keywords:
CDIClostridium difficilevaccine

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K

Related Experiment Videos

Last Updated: May 2, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

9.3K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K

Area of Science:

  • Microbiology
  • Immunology
  • Infectious Diseases

Background:

  • Clostridium difficile infection (CDI) is a significant cause of hospital-acquired illness, ranging from diarrhea to severe colitis.
  • Emerging C. difficile strains have increased disease incidence, severity, and mortality, complicating treatment.
  • Limited effective drugs and rising antibiotic resistance necessitate novel therapeutic approaches for CDI.

Purpose of the Study:

  • To review recent advancements in the development of vaccines against Clostridium difficile infection.
  • To identify current challenges and future perspectives in CDI vaccine research.
  • To discuss the potential of newly identified candidate antigens for vaccine development.

Main Methods:

  • Literature review of recent research on C. difficile vaccines.
  • Analysis of experimental vaccine development and clinical trial progress.
  • Evaluation of emerging C. difficile antigens for immunotherapeutic potential.

Main Results:

  • Several experimental C. difficile vaccines have been developed.
  • Three C. difficile vaccines are currently undergoing clinical evaluation.
  • New candidate antigens are being identified for future vaccine strategies.

Conclusions:

  • Active vaccination presents a viable strategy for preventing Clostridium difficile infection.
  • Ongoing research and clinical trials are crucial for advancing CDI vaccine efficacy.
  • Novel antigens hold promise for next-generation C. difficile vaccines to address treatment resistance and recurrence.